Purpose: Mesothelioma is an incurable cancer involving the lining of the lung. Patients usually suffer progressive symptoms of shortness of breath and chest pain, until they ultimately succumb to the disease. While a very small number of patients qualify for aggressive treatment with surgery, chemotherapy and radiation, and enjoy long-term survival, the vast majority of patients have incurable disease. The treatment options currently available, including chemotherapy and radiation treatment, are only modestly effective at alleviating symptoms and improving life expectancy. This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy’s ability to treat unusual shaped tumours, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness. We will treat 17 patients with tomotherapy and assess the breathing, symptoms, and quality of life of the patients before and after treatment
From the blog
Women three times more likely to survive mesothelioma than men
The prognosis for mesothelioma is grim- only 40 percent of all victims survive the first year with the average dwindling to eight percent after three years. Different studies varied in their conclusions about whether men or women survive longer. Recognizing none of the existing studies were population-based, researchers decided to[…]
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Purpose: The goal of this clinical research study is to learn if the Wilms Tumor-1 (WT1) vaccine, when given in combination with montanide and GM-CSF, can help to prevent or delay mesothelioma from coming back after surgery and treatment. The safety of this vaccine will also be tested.
Montanide and GM-CSF are designed to cause white blood cells to grow, which may help to increase the immune response.
WT1 is a protein in cancer cells that regulates gene expression and causes cell growth. Mesothelioma tumors usually have high levels of WT1. The WT1 vaccine is designed to cause the increased immune response created by other drug combinations (like montanide and GM-CSF) to be directed at mesothelioma.
New mesothelioma detection method exposes subjects to less radiation
To monitor a patient for mesothelioma involves subjecting them to CT scans with high levels of radiation. Repeated screenings increase risks for other health issues. For workers exposed to asbestos, these scans are necessary for survival even with the drawbacks. A study out of France found a new CT method[…]
Vinorelbine in Mesothelioma (VIM)
Purpose: This study is for patients with malignant mesothelioma of the lung lining (called pleura) who have had previous chemotherapy with a platinum-based regimen whose disease has progressed. Malignant pleural mesothelioma (MPM) is an aggressive, frequently drug resistant, and incurable disease that is increasing in incidence in the UK and worldwide. All patients with MPM will relapse following first line chemotherapy and at present, there is no standard treatment available for patients in the second line setting. The vinca alkaloid chemotherapy drug vinorelbine has shown promising activity in a single arm UK trial. However to date, there has been no randomised evaluation of vinorelbine in mesothelioma in the second line setting. In addition, there have been no trials which have looked at underlying molecular changes in mesothelioma which may predict vinorelbine efficacy; This might allow vinorelbine to be used in patients only where there is a chance of benefit. Studies suggest that vinorelbine requires a gene called BRCA1 (shown to be absent in 38% of mesothelioma cases) in order to induce cell death in mesothelioma. The VIM trial aims to establish whether vinorelbine in patients with MPM helps them live longer and whether the BRCA1 gene is helpful in selecting patients most likely to benefit from treatment.
Patients will be randomised (1:2) to receive either active symptom control (ASC) (which is all supportive care deemed necessary for pain management excluding disease modifying treatment) or ASC with vinorelbine. Patients will continue vinorelbine treatment until evidence of disease progression (or unacceptable toxicity to the drug or patient withdrawal). If vinorelbine activity is demonstrated, we will use the results from this trial to inform the design of a future phase III trial.
Yale won’t revoke honorary degree from a man who caused an asbestos environmental disaster
In 1996, Yale awarded Stephan Schmidheiny an honorary Doctorate of Humane Letters for his work in promoting stewardship for the environment. Many praised Schmidheiny based on his efforts to protect the planet and even referred to him as the Bill Gates of Switzerland. A verdict received in 2012 changed the[…]
Threat of mesothelioma a lifetime fear
Developing mesothelioma after asbestos exposure is a known occurrence, yet little research is conducted to evaluate the risk period after first exposure. Scientists in Italy and Australia studied more than 20,000 people exposed to asbestos and more than 800 patients diagnosed with mesothelioma to determine the long-term risks. Based on[…]
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Purpose: This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against the tumor-associated antigen mesothelin, which has been shown to be present at higher levels on certain tumor cells (such as mesothelioma) than on normal cells. Pemetrexed and cisplatin are the standard chemotherapy regimen to treat malignant pleural mesothelioma. This trial will evaluate whether giving CRS-207 cancer vaccine with chemotherapy will induce anti-tumor immune responses and/or objective tumor response.
New method to diagnose mesothelioma
Mesothelioma is a death sentence to most who receive the diagnosis. Taking decades to develop, many visit the doctor after suffering from shortness of breath not realizing past asbestos exposure sealed their fate. Many tests exist to determine the mesothelioma diagnosis, such as imaging and bloodwork, but a tissue biopsy[…]
Firefighters at higher risk for many cancers including mesothelioma
When the alarm sounds, they don’t think about the dangers ahead or their possible loss of life. Firefighters immediately react, placing the lives of those in peril ahead of their own. They charge into burning buildings with one goal in mind, not pausing to consider the longterm effects. Unfortunately for[…]
Skip to content